Looking for predictive markers in breast cancer – Authors' reply

Chikako Suzuki, Lennart Blomqvist, Thomas Hatschek, Lena Carlsson, Zakaria Einbeigi, Barbro Linderholm, Birgitta Lindh, Niklas Loman, Martin Malmberg, Samuel Rotstein, Martin Söderberg, Marie Sundqvist, Thomas M. Walz, Gunnar Åström, Hirofumi Fujii, Hans Jacobsson, Bengt Glimelius, Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy Medical Oncology. ,vol. 30, pp. 415- 415 ,(2013) , 10.1007/S12032-012-0415-5

Joseph Gligorov, Dinesh Doval, José Bines, Emilio Alba, Paulo Cortes, Jean-Yves Pierga, Vineet Gupta, Rômulo Costa, Stefanie Srock, Sabine de Ducla, Ulrich Freudensprung, Giorgio Mustacchi, Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 15, pp. 1351- 1360 ,(2014) , 10.1016/S1470-2045(14)70444-9

F. Puglisi, G.G. Cardellino, D. Crivellari, C. Di Loreto, M.D. Magri, A.M. Minisini, M. Mansutti, C. Andreetta, S. Russo, D. Lombardi, T. Perin, G. Damante, A. Veronesi, Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer Annals of Oncology. ,vol. 19, pp. 1541- 1546 ,(2008) , 10.1093/ANNONC/MDN165

Rupert Bartsch, Guenther G Steger, Birgit Forstner, Catharina Wenzel, Ursula Pluschnig, Blanka Rizovski, Gabriela Altorjai, Christoph C Zielinski, Robert M Mader, Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel BMC Clinical Pharmacology. ,vol. 7, pp. 7- 7 ,(2007) , 10.1186/1472-6904-7-7

H. Ishitsuka, T. Ishikawa, M. Nishida, N. Sawada, Yu Fukase, T. Yoshikubo, Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clinical Cancer Research. ,vol. 4, pp. 1013- 1019 ,(1998)

Istvan Lang, Thomas Brodowicz, Larisa Ryvo, Zsuzsanna Kahan, Richard Greil, Semir Beslija, Salomon M Stemmer, Bella Kaufman, Zanete Zvirbule, Günther G Steger, Bohuslav Melichar, Tadeusz Pienkowski, Daniela Sirbu, Diethelm Messinger, Christoph Zielinski, Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial Lancet Oncology. ,vol. 14, pp. 125- 133 ,(2013) , 10.1016/S1470-2045(12)70566-1